TP5, a Peptide Inhibitor of Aberrant and Hyperactive CDK5/p25: A Novel Therapeutic Approach against Glioblastoma

We examined the efficacy of selective inhibition of cyclin-dependent kinase 5 (CDK5) in glioblastoma by TP5. We analyzed its impact in vitro on CDK5 expression and activity, cell survival, apoptosis and cell cycle. DNA damage was analyzed using the expression of γH2A.X and phosphorylated ATM. Its to...

Descripción completa

Detalles Bibliográficos
Autores principales: Tabouret, Emeline, Wang, Herui, Amin, Niranjana, Jung, Jinkyu, Appay, Romain, Cui, Jing, Song, Qi, Cardone, Antonio, Park, Deric M., Gilbert, Mark R., Pant, Harish, Zhuang, Zhengping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409269/
https://www.ncbi.nlm.nih.gov/pubmed/32708903
http://dx.doi.org/10.3390/cancers12071935

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409269/
https://www.ncbi.nlm.nih.gov/pubmed/32708903
http://dx.doi.org/10.3390/cancers12071935

Ejemplares similares